"We are delighted that Dr. Rothenberg will be joining Pfizer's Oncology Business Unit and are confident that his unique background and experience will play a pivotal role in the development of more innovative drugs," said Garry Nicholson, senior vice president, general manager of the Oncology Business Unit. "As we continue to progress in oncology, our primary focus is on advancing science so that we can address the unmet medical needs and bring medicines to patients faster."

Dr. Rothenberg has been active in clinical-translational research in oncology for more than 20 years. He has been the recipient of several research grants from the National Cancer Institute and has served as a reviewer on several NIH study sections. He has published more than 150 articles and book chapters, primarily in the areas of early stage drug development, gastrointestinal malignancies and ovarian cancer. He has served on the editorial boards of several leading medical journals, including the Journal of Clinical Oncology, and Clinical Cancer Research. Dr. Rothenberg's work was critical to the development and eventual FDA approval of irinotecan (CPT-11, Camptosar(R) in 1996 and oxaliplatin (Eloxatin(R) in 2002 for colorectal cancer and gemcitabine (Gemzar(R) in 1996 for pancreatic cancer. In addition to his clinical research accomplishments, Dr. Rothenberg has also been recognized for his compassionate care of cancer patients. In 2008, Dr. Rothenberg received the Lane W. Adams Quality of Life Award from the American Cancer Society, honoring him as one of the nation's top cancer caregivers.

"My entire career has been devoted to developing new and better cancer therapies on a patient by patient, study by study basis. With this opportunity at Pfizer, I will have the chance to oversee development of new therapies on a worldwide scale with a family of compounds that is one of the best in the industry. This is not only a great opportunity but also a great responsibility. To help accomplish this, I will work to forge collaborations between Pfizer and the best cancer research centers in the world to develop new, more effective therapies for patients with cancer," Dr. Rothenberg said.

Dr. Rothenberg received his B.A. from the University of Pennsylvania magna cum laude in 1978, his M.D. from the New York University School of Medicine in 1982, and trained as an Intern and Resident in Internal Medicine at Vanderbilt University from 1982 to 1985. He obtained his medical oncology training at the National Cancer Institute from 1985 to 1988 and served as Special Assistant to the Director, Division of Cancer Treatment from 1988 to 1991. In 1991, he moved to San Antonio where he was appointed Assistant, then Associate Professor in the Department of Medicine, Division of Medical Oncology at the University of Texas Health Science Center in San Antonio and Executive Officer of the Southwest Oncology Group. In 1998, Dr. Rothenberg returned to Vanderbilt where he is currently Professor of Medicine, Ingram Professor of Cancer Research, Director of Phase I Drug Development, Co-Leader of the Experimental Therapeutics Program, and Co-Principal Investigator of the Vanderbilt SPORE in Gastrointestinal Cancer.

About Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of treatments and currently has 47 innovative compounds in development across four platforms. These agents target more than 20 different cancer-related pathways. By leveraging the strength of our resources and scientific talent, Pfizer Oncology strives to discover and develop novel treatment options to improve the outlook for oncology patients. Pfizer currently devotes more than 22 percent of their total R&D budget to the field of oncology, investing $1.67 billion annually in worldwide research initiatives. We also partner with healthcare providers, governments and local communities around the world to provide better quality healthcare and health system support.

SOURCE: Pfizer

Pfizer 
Media: 
Vanessa Aristide, 212-733-3784 
or 
Investors: 
Jennifer Davis, 212-733-0717

Key Topics Covered:

The report is divided into two colour-coded sections for your ease of use, Sector Analysis and Individual Company Analysis.

Sector Analysis: Sales growth, market share and profitability are all analysed over a 10 year period giving you the fullest picture possible of the health of the market. Companies are ranked on these categories so you can see which companies are outshining the rest. Use the industry average tables to benchmark your own company's performance- how do you compare to the rest of the industry?

Industry Analysis: Each company receives a full page of analysis, evaluating their financial performance over the last five years so you get a full picture of the long term prospects of each company. Each company page of analysis is also packed with the following information: Full business name and address, Names and ages of directors, contact details and website address, seven unique Plimsoll charts showing at a glance the performance of each company, averages for the industry are also shown indicating the bare minimum each company should be looking to achieve, and five years of the latest accounts available, New! Written summary on each company highlighting their key strengths and weaknesses.

Companies Mentioned:

- ACRE MILLS (UK)

- AQUILA BUSINESS PRODUCTS

- ARC TRADING

- BARSON PRESS(LEEDS)

- BEN JOHNSON

- BOLDLIKE

- BRADBURY WINSLOW

- BRANDED CONSUMABLE GOODS (DIRECT)

- CARSON STATIONERY & PRINT

- CARTRIDGE WORLD

- CENTREREED

- COMPLETE OFFICE SOLUTIONS UK

- COMTEXT SERVICES

- CRESCENT OFFICE SUPPLIES

- CUSTOM BUSINESS EQUIPMENT AND STATIONERY SUPPLIES

- D3 OFFICE GROUP

- DALES OFFICE SUPPLIES AND EQUIPMENT

- DRAWING GROUP (UK)

- (THE) DURAWELD

- EAGLE OFFICE SUPPLIES

- F B JESPER & SON

- F B JESPER & SON (COMMERCIAL)

- F B JESPER & SON (HOLDINGS)

- FINDEL EDUCATION GROUP

- FINDEL

- FIREGABLE

- FORMKRAFT DISTRIBUTION

- FRANK BERRY (OFFICE SUPPLIES)

- GEORGE VYNER (2006)

- GEORGE VYNER(DISTRIBUTORS)

- H TURNER & SON

- HAGUE COMPUTER SUPPLIES

- HAGUE PRINT MEDIA SUPPLIES

- HARRIS COURT

- HILLS OFFICE SUPPLIES

- IMCOPEX OFFICE SUPPLIES

- ISA TRADING

- J A MAGSON

- J J NEWLAND

- JENKINSON MARSHALL & CO

- JOHN W ADAMS

- JOWETT & SOWRY

- MAHDLO

- MARTIN REPROGRAPHICS

- MEDIA HISTORY

- MIDAS PAPER CONVERTERS

- MIKE PAGE OFFICE SUPPLIES

- NEAT IDEAS

- NORTH SPEED DISTRIBUTION (LEEDS)

- PAGE PAPER

- PETER TEBAY

- PHOENIX OFFICE SUPPLIES

- PREMIER ROLLS

- PREMIER ROLLS (SOUTH)

- RICHARD WILD (STATIONERS)

- SELECT BUSINESS PRODUCTS

- SHARED EARTH

- STRATSOURCE

- TANYARD STATIONERS

- TECHNOPRINT

- THOMAS DICK (YORK)

- TIGERPRINT

- TIGERPRINT MIDDLE

- TILL ROLL CO

- (THE) TRUE PRINT

- UK GREETINGS

- VENRIDGE HOLDINGS

- VENRIDGE

- WHITE & FARRELL

- WILLIAM SINCLAIR & SONS (STATIONERS)

- WM HARRISON & SON (RIPON)

- WRIGHT PRINTING SERVICES

- YORKSHIRE BUSINESS EQUIPMENT

For more information visit http://www.researchandmarkets.com/research/de7384/office_supplies_y

SOURCE: Research and Markets Ltd.

Research and Markets 
Laura Wood 
Senior Manager 
press@researchandmarkets.com 
Fax from USA: 646-607-1907 
Fax from rest of the world: +353-1-481-1716